Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY07121 in Advanced Solid Tumors
NCT06639256Phase 2Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of HY-07121 in solid tumor (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events up to 2 years and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
HY-07121
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06639256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639256.